MedTrace Logo

Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis

NCT06573164 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-08-27

No results posted yet for this study

Summary

Allergic rhinitis and asthma are common respiratory diseases. Qipian® is a Chinese medicine made from three types of bacteria, used to treat these conditions. This study will retrospectively analyze the effects of adding Qipian® to the regular treatment for patients with allergic rhinitis, with or without asthma. Patients meeting the Allergic Rhinitis and its Impact on Asthma（ARIA） and Global Initiative for Asthma（GINA） diagnostic criteria were divided into two groups: one receiving standard drug treatment, and the other receiving standard treatment plus Qipian®. The study will compare clinical symptoms and relevant blood markers before and after treatment to see if adding Qipian® leads to better outcomes than the standard treatment alone.This study aims to determine how Qipian® benefits patients with rhinitis and asthma and its effect on related serum indicators, helping to explore its role in allergic respiratory diseases.

Conditions

Interventions

DRUG

Bacillus clausii tablets（Qipian®）

Take 4 tablets (0.3 mg each) orally three times daily.

DRUG

conventional medication

Use conventional medication as needed based on the patient's condition.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Huiying Wang · 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06573164 on ClinicalTrials.gov